In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

Swiss pharma major Roche (ROG: SIX) has outlined ambitious plans to accelerate the development of trontinemab, its ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Roche Holdings AG said it will begin a late-stage trial to evaluate whether its experimental Alzheimer’s drug, trontinemab, ...

Roche also announced that it would initiate a Phase 3 program for trontinemab, which is expected later this year.

Preliminary results for trontinemab from 114 participants in the 1.8 or 3.6 mg/kg suggest a rapid and deep, dose-dependent reduction of amyloid plaques in the brain as measured by amyloid positron ...

Roche anticipates tests being available in Europe by late 2025, with the U.S. following after. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks.

(Reuters) -Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer ...

Major health news includes Roche's plan to test a drug for Alzheimer's, a US data-sharing initiative in healthcare, Nordic ...

Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...

A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the ...